administration with propranolol (peak dose 80 mg/day) to individuals undergoing a rigorous cancer treatment -autologous hematopoietic cell transplantation -for multiple myeloma. Twenty-two patients have been enrolled (target accrual = 25). 199 individuals completed screening between July 2015 and January 2017; 16 patients declined study participation and 28 enrolled in other oncology treatment trials. Of the remaining 155 patients, 132 were ineligible. The most common reason for ineligibility was current betablocker usage (44; 22% of total screened). Of the 23 eligible patients who did not decline or enroll in another trial, 22 were successfully enrolled in the propranolol trial (96%). One of the 11 patients in the treatment arm was unable to complete the propranolol course due to hypotension; >90% of treatment arm patients were compliant with all 5 weeks of propranolol administration. In sum, adjunctive PNI pharmacologically-based cancer trials may compete for enrollment with primary oncology treatment trials, though enrollment is feasible and cancer patients undergoing rigorous antineoplastic treatment tolerate and are compliant with concurrent beta-blocker therapy.
Like many biological processes, sleep shows relationships with immunity and inflammation. Using public NHANES data (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) ; n = 28,351, ages 18+), we tested the hypothesis that sleep quality and duration would be associated with immunological markers, health, and mortality. Linear regression and logistic regression models were used to analyze all relationships. Since the NHANES is a complex survey design, all estimates are corrected to be representative of the US adult population and standard errors are calculated using the Taylor Series approximation. After controlling for physical health, sex, ethnicity, and depression, sleep disorders were positively associated with increased white blood cells, lymphocytes, monocytes, neutrophils, and eosinophils, as well as self-reported illnesses during the past month and mortality from multiple biological causes (all p < 0.05). Self-reported weekday hours slept was negatively associated with self-reported illnesses, white blood cell counts, and neutrophil and lymphocyte numbers (all p < 0.05), and showed a U-shaped relationship with mortality. White blood cell, monocyte, and neutrophil counts predicted mortality, even after controlling for sleep measures, indicating that immune activation contributes to, but is not solely responsible for, the relationship between sleep and mortality. This large, crosssectional analysis suggests that short or disturbed sleep predicts an immunologically active state. This homeostatic disturbance could increase vulnerability to some illnesses, including infectious diseases, and persistent disruptions may be partly responsible for increased mortality. Inflammatory cytokines are commonly elevated in acute depression and are associated with resistance to monoaminergic treatment. To examine the potential role of cytokines in the pathogenesis and treatment of depression, we carried out a systematic review and meta-analysis of antidepressant activity of anti-cytokine treatment using clinical trials of chronic inflammatory conditions where depressive symptoms were measured as a secondary outcome. Systematic search of the PubMed, EMBASE, PsycINFO and Cochrane databases, search of reference lists and conference abstracts, followed by study selection process yielded 20 clinical trials. Random effect meta-analysis of seven RCTs involving 2370 participants showed a significant antidepressant effect of anti-cytokine treatment compared with placebo (standardised mean difference (SMD) = 0.40, 95% confidence interval (CI), 0.22-0.59). Anti-TNF drugs were most commonly studied (five RCTs); SMD = 0.33 (95% CI, 0.06-0.60). Separate meta-analyses of two RCTs of adjunctive treatment with anti-cytokine therapy and eight non-randomised and/or non-placebo studies yielded similar small-to-medium effect estimates favouring anti-cytokine therapy; SMD = 0.19 (95% CI, 0.00-0.37) and 0.51 (95% CI, 0.34-0.67), respectively. Adalimumab, etanercept, infliximab and tocilizumab all showed statistically significant improvements in depressive symptoms. Furthermore, antidepressant effect was associated with depressive symptom severity at baseline (p = 0.018) but not with improvement in primary physical illness, sex, age or study duration. The findings indicate a potentially causal role for cytokines in depression and that cytokine modulators may be novel drugs for depression in chronically inflamed subjects.
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